Clairity Breast becomes the first FDA-authorized AI software to predict five-year breast cancer risk using routine mammography images.
Key Details
- 1FDA grants de novo authorization to Clairity Breast, developed by Boston-based Clairity.
- 2The AI tool analyzes mammogram images for subtle features correlated with future cancer risk.
- 3Unlike traditional models, Clairity Breast does not require age or genetic data.
- 4The system was trained on millions of mammogram images linked to five-year outcomes.
- 5Clairity Breast delivers validated risk scores to radiologists through standard clinical systems.
- 6Commercial launch is targeted for the end of 2025.
Why It Matters
This breakthrough FDA authorization marks a new era in preventive oncology by enabling earlier risk identification using only imaging, potentially improving precision prevention and patient outcomes in breast cancer care.
Source
Radiology Business
Related News
•Radiology Business
Framework Assesses Real-World Financial Impact of Radiology AI Adoption
A new analysis presents a financial calculator for objectively assessing the return on investment (ROI) of implementing radiology AI solutions.
•Radiology Business
Radiology Dominates FDA AI Algorithm Clearances in 2026
Radiology accounted for 68 new FDA-cleared AI algorithms in early 2026, making up more than three-quarters of all AI clinical clearances.
•Radiology Business
Private Equity Backs AIRS Medical to Expand MRI AI Globally
TA Associates is investing in AIRS Medical to accelerate its global expansion of AI-powered MRI efficiency solutions.